Articles About Medtech

Five Reasons Why This Pharmaceutical Specialist Could Double Your Money in Just Two Years

0 | By Michael A. Robinson

In our twice-weekly chats, I often suggest investments that are part of large tech sectors.

For instance, the life sciences field defines huge. Just the prescription drug segment alone will be worth $1.2 trillion by 2024, according to data from Statista.

So, you might be wondering why I am focused on a medical area that will be worth just 0.1% of that figure over roughly the same time frame.

It’s a fair question. The answer is pretty basic. A high-octane leader
focused on specialty drugs can make a killing.

And the one I’m going to reveal to you today defines profit machine. It’s on pace to double per-share earnings in as little as a year.

With that in mind, let me show you five reasons why this wealth-building biotech firm should at the very least be on your radar screen….

This Stock Crushed the Broader Market – And Now It’s Helping Exhausted Healthcare Workers

0 | By Michael A. Robinson

I want to start today’s chat with a tech-investing challenge.

How many of you can claim you have a stock in your portfolio that is up nearly 230% in just 16 months?

As impressive as that return sounds, it actually understates the strength of the stock I have in mind. It’s a medical device leader that recently received approval for a Covid-19 test.

It’s up 120 in the past two months alone…

But this is no flash in the pan. Even before that breakthrough occurred, the stock was a bona fide market crusher

From roughly the beginning of 2019 through the correction that began on February 19, the stock was ahead of the S&P 500 by an amazing 278.5%.

The firm I have in mind is leading the medical device market as part of a trend toward remote patient monitory.

With the coronavirus still fresh on everyone’s minds, the investment thesis is only getting better.

So, today I’m going to reveal why the stock could double in as little as three years and show you how to get in on the action

The High-Tech Outlook for the Coronavirus Crisis: Part 2

0 | By Michael A. Robinson

When we spoke on Tuesday, I made a bold prediction: the Covid-19 outbreak, while serious, will not be as bad as the worst-case predictions would have it.

For one, much of the country is already on lock-down, cutting off the spread of the disease. That is buying us some valuable time as researchers race to find a cure or at least a good treatment option.

And I’m happy to report there have been some exciting developments in the search for treatments and vaccines against Covid-19

Last week, I noted that most vaccine research remains rooted in 1950s technology.

Despite mapping the entire human genome back in April 2004, drug firms and scientists still rely on slowly growing viruses inside chicken eggs to create a vaccine.

This takes a lot of time – and a lot of eggs.

But the Covid-19 pandemic has them racing to find a treatment using novel and fascinating science.

With that in mind, today I want to take a closer look at some of the promising 21st Century research pushing the boundaries of this field

Five Good Reasons to Ignore a High Price Tag When Looking for Winning Tech Plays

0 | By Michael A. Robinson

My wife and I recently helped our daughter Jordan find a reliable used car.

And since Jordan only recently got her grad degree, I have to say she was pretty price sensitive.

She had roughly $9,000 to put down and wanted to limit her payments to about $100 a month, so there wasn’t a lot of wiggle room on cost. She bought, a 2009, one-owner, fully loaded Honda CRV with only 45,000 miles on it.

I’m bringing this up to you because I think our recent experience illustrates a very important point for tech investors.

When it comes to putting your money in stocks that can crush the market, don’t let high “sticker prices” warn you off of great opportunities to build lasting wealth.

Instead, you have to focus on the long-term upside. You know, it’s the old saw by Warren Buffett that price is what you pay but “value is what you get.”

And that really comes into play with a firm that is pioneering the field of robotic surgery.

At first glance, $600 a share seems steep. But this is a stock that could hit $1,800 a shares in as little as seven years.

Today, I’m going to reveal five reasons why we could see a 200% return from here

My Readers had the Chance to Crush the Market by 186% in 2019, but 2020 Looks Even Brighter

0 | By Michael A. Robinson

There’s no doubt about it. We are living in a time of astounding financial opportunities.

Last year, was a great one year for the average retail investor, continuing the epic bull market that began in March 2009. As we move into 2020, it looks like it has the potential to keep right on going.

The terrific economy that we’ve had has helped propel stocks to record highs. Unemployment remains at 50-year lows as real income adjusted for inflation is moving up for millions of Americans.

In a case like this, you’d think all you have to do from here on out is just coast on autopilot. After all, the bellwether S&P 500 was up roughly 28.9% for the year as of the close on December 31.

But, as impressive as that sounds, you could do much better in 2020.

That’s because the S&P 500’s numbers for the year are nothing compared to the gains members of my monthly tech investing newsletter, the Nova-X Report, scored in 2019.

Indeed, our three best performers for the year more than doubled the S&P.

With that in mind, today I want to reveal three stocks that made my Nova-X members tons of cash and show you how to get in on all the action

Get in On This Medical Breakthrough Before It Hits the Market

1 | By Michael A. Robinson

Imagine if all it took to treat a case of cancer was taking out the trash.

Now I want you to imagine that your body could do it all for you.

Hold that thought. Because a tech platform with that very task in mind is set to hit the market sooner than you think and will target a field set to be worth more than $160 billion.

Here’s the thing. Several life sciences firms are hard at work perfecting a new class of drugs known as “degraders.”

Let me explain. The root of many diseases lies in misguided proteins that bind together. So, the idea here is to come up with a new class of drugs that activate the body’s own molecular trash disposal systems.

This is one of the most exciting breakthroughs I’ve come across in many years. I believe it puts us close to the day when one pill can cure dozens, if not all, diseases.

And in a moment, I’m going to reveal a way investors can target the entire class of protein degraders with one savvy move

You Can Double Your Money Fighting the $1.1 Trillion Disease Killing America

0 | By Michael A. Robinson

I recently got the kind of news that no child wants to hear about an aging parent.

Here’s the thing, I count my blessings that my dad lived so long. After all, he’s a retired Marine Corps captain who saw three tours of combat, one in Korea and two in Vietnam.

Honestly he’s lucky he lived as long as he did. But that still doesn’t make the aging process any easier, at least not on the body.

He recently had a second knee replacement that didn’t go as well as planned. He also has swelling of the feet. His mobility is not all that great, and he can’t drive right now.

At 86, he recently learned he has congestive heart failure. That’s a condition in which the heart doesn’t pump as strongly as it should, leading to a buildup of fluids.

As such, my dad is part of a huge trend in America. Fact is, according to the American Heart Association, cardiovascular disease is set to have an economic impact of $1.1 trillion by 2035.

And today, I want to reveal a life sciences firm that is bringing badly needed relief to millions of heart patients, and show you five reasons why it’s set to double in as little as 3.5 years

The Answer to Big Pharma’s Biggest Problem Could Double Your Money in just Three Years

0 | By Michael A. Robinson

You could forgive drug and biotech executives for having a bad case of target fixation.

After all, they do work in a field that is filled with time-consuming and expensive headaches.

Consider that the Biotechnology Innovation Organization (BIO), the world’s largest biotech trade organization, looked at 7,400 drug programs by 1,103 companies. They were investigating drug-approval rates.

The news was not good -just 9.6% of drugs scientists discover ever get approved for sale. That’s a one-in-ten shot.

With such daunting data, it’s no wonder that, even in a field already worth $1.2 trillion in global sales, industry leaders are on the lookout for ways to lower the cost of discovery and shorten time to market.

And with that goal in mind, I’ve uncovered a high-octane, large-cap firm that has become an essential ingredient in the drug sector’s success.

It’s a cloud-based leader in pharmaceutical efficiency that has a history of crushing the market by no small measure. It’s been doubling its earnings, on average, every 18 months

It’s a cloud-based leader in pharmaceutical efficiency that has a history of crushing the market by no small measure. It’s been doubling its earnings, on average, every 18 months

My Top Three Recommendations for New Investors

0 | By Michael A. Robinson

My “dad vibe” must be working overtime these days.

And that’s got me thinking maybe my “chance” conversations with a number of young adults lately is a sign of the times.

Let me explain.

As I’ve been going about my routines in the past, I’ve run into a lot of young people who want to get started in investing, but have no clue how to do so.

I’m talking about folks my daughters’ age who are earning some income and want to invest, but just don’t know where to start.

For instance, once, while skiing at the Kirkwood Mountain Resort near Lake Tahoe, I chatted with three young adults who jumped at the chance to get my advice about investing.

I guess that’s where the dad vibe comes into play…. I told them about a surefire way to make the market work for them as though I were talking to my own daughters.

And it just so happens that this investment advice is good for newcomers and old, particularly investors who’ve been reluctant to jump in when market conditions are so volatile.

That’s why today, I’m going to show you not just the one “starter” investment vehicle I suggest for young adults that can set you on the right track…

But I’m going to recommend three other tech-centric ways to jump start your portfolio right now…

Check it out

The “Printing” Tech Tackling Heart Disease’s $400 Billion in Annual Costs

0 | By Michael A. Robinson

There’s a new cutting-edge tech breakthrough that could save the lives of six million Americans in a decade.

Yes, it is potentially a very powerful weapon in the fight against heart disease, which the U.S. Centers for Disease Control and Prevention says causes one in four deaths each year.

Ironically, the technology is in a sector deeply out of favor with Wall Street.

But that’s just fine with us. At Strategic Tech Investor, we know the huge profit potential in bucking the Street’s herd mentality.

And you couldn’t pick a more exciting field than 3D-printed human organs.

Here’s the thing. Scientists in Israel printed a tiny heart in April, complete with blood vessels, using a patient’s cells.

Even better, they pulled off this amazing achievement in just three hours.

That’s why today, I’m going to show you what I believe is the best market-crushing play on the future of 3D printing tech used to save lives…

Check it out